title: Clinical Impact of Solifenacin on Generic and Symptom-Specific Quality of Life for Females with Overactive Bladder: Using the Overactive Bladder Symptom Score and Rand Medical Outcomes Study 36-Item Health Survey.
abstract: OBJECTIVE
  We evaluated the effectiveness of antimuscarinic treatment on disease-specific and generic quality of life (QoL) in females with clinically diagnosed overactive bladder (OAB) by prospectively analyzing improvements in the overactive bladder symptom score (OABSS) and the Rand Medical Outcomes Study 36-Item Short Form Health Survey (SF-36).
  
  
  METHODS
  We prospectively recruited newly diagnosed female patients with OAB. Pretreatment disease-specific symptoms were documented, and generic QoL questionnaires were administered. All subjects received solifenacin 5 mg/day for >8 weeks. Symptoms and general health-related QoL (HRQoL) were assessed using the OABSS and SF-36, respectively. Other objective variables, such as maximum urinary flow rate and postvoid residual urine volume, were also evaluated.
  
  
  RESULTS
  Seventy-eight subjects met all inclusion criteria and no exclusion criteria. After 8 weeks, the mean OABSS decreased by approximately 50% compared with baseline (from 9.1 ± 2.8 to 4.5 ± 3.6). All individual scores in OABSS improved after administration of solifenacin. Before treatment, the scores of the study subjects in all SF-36 domains were significantly worse than the age- and gender-adjusted Japanese national norms (P < 0.01), except the vitality (VT) scale. Intra-group comparisons between age groups showed worse mental health (MH) scores in all age groups. In the OAB group, three mean SF-36 scales (physical function [PF], VT, and MH) significantly improved after treatment.
  
  
  CONCLUSIONS
  Treatment of OAB with solifenacin is associated with significant improvement in generic HRQoL and disease-specific symptoms at 8 weeks after drug administration. Particularly for generic HRQoL as measured by the SF-36, solifenacin treatment effectively improves three SF-36 scores: PF, VT, and MH.
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Yano
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Suzuki
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Naoto
authors.initials: N
authors.lastname: Kamiya
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Tomonori
authors.initials: T
authors.lastname: Kato
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Kazushi
authors.initials: K
authors.lastname: Nomura
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kuramochi
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Sho
authors.initials: S
authors.lastname: Ohta
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Mikami
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Hiroomi
authors.initials: H
authors.lastname: Nakatsu
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Okano
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Onishi
authors.affiliation: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, JapanChiba Continence Research Society, Chiba-shi, JapanDepartment of Urology, Chiba University Graduate School of Medicine, Chiba-shi, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Ichikawa
keywords: Rand Medical Outcomes Study 36-Item Short Form Health Survey; antimuscarinic agent; overactive bladder; overactive bladder symptom score; quality of life